Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 4

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 16Lymphoid 10Myeloid 5Thoracic 4Gynecologic 4Gastrointestinal 4Plasma cell 3Breast 3Head & Neck 2Genitourinary 2Dermatologic 2Sarcoma 1Classical hematology 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Tumor Virus Infections 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Microsatellite Stable Colorectal Carcinoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 1409Fluorouracil 1298Capecitabine 1085Gemcitabine 1042Leucovorin 928Irinotecan 815Bevacizumab 803Cisplatin 666Radiotherapy 535Cetuximab 469pembrolizumab 428Paclitaxel 389Nivolumab 336130-nm albumin-bound paclitaxel 322Drug Therapy 314Docetaxel 286S 1 (combination) 273Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 209Surgical Procedures, Operative 203tislelizumab 202Radiosurgery 202lenvatinib 201apatinib 198Carboplatin 186Magnetic Resonance Spectroscopy 181regorafenib 180

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × cc-486 × Gastrointestinal × Clear all
NCT02512172 2025-12-03

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
27 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01845805 2022-10-04

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
49 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02811497 2021-04-01

METADUR

University Health Network, Toronto

Phase 2 Completed
28 enrolled
BreastGastrointestinalGynecologic

Microsatellite Stable Colorectal Carcinoma

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡